Our Mission

VantAI's mission is to unlock a new chapter in medicine by making protein interactions programmable

Inducers

Modulators

Blockers

An Integrated Discovery Platform

Three complementary, phase shifting technologies…

…built to unlock the full potential of the proximity modulator modality

Working With Industry Leaders

BUILD THE FUTURE WITH US

Latest News

March 21, 2025
VantAI Launches Neo-1
VantAI launches Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation for therapeutic design.
May 22, 2024
VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AI
VantAI, a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).
May 08, 2024
VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery
VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.

Generative AI in Drug Discovery Lecture Series

Dive into our premiere episodes of a monthly lecture series dedicated to Generative AI in Drug Discovery

About Us

If you are looking for a role at the bleeding edge of artificial intelligence, where your impact is immediate and meaningful, this is it.

Apply your skills to help us tackle some of the most complex and meaningful scientific challenges on the planet.